Hydromorphone is a strong opioid pain medication used to treat severe pain that hasn’t responded adequately to other painkillers. It’s roughly 5 to 7 times more potent than morphine on a milligram-for-milligram basis when taken by mouth, which makes it one of the stronger prescription opioids available. You may recognize it by the brand name Dilaudid.
Primary Use: Severe Pain Management
Hydromorphone is FDA-approved specifically for pain severe enough to require daily, around-the-clock opioid treatment when other options, including non-opioid pain medicines and shorter-acting opioids, haven’t provided enough relief or can’t be tolerated. That’s a narrower indication than many people expect. It isn’t designed for occasional or mild-to-moderate pain. It’s reserved for situations where the pain is persistent, intense, and not controlled by less powerful alternatives.
In practice, this means hydromorphone is most commonly prescribed for cancer-related pain, severe post-surgical pain, major trauma, and certain chronic pain conditions that have failed other treatments. In hospitals, it’s frequently given by injection for acute situations like severe injury, kidney stones, or pain following major surgery. The extended-release tablet form is reserved for patients who are already opioid-tolerant, meaning they’ve been taking opioid medications regularly and their bodies have adjusted to that class of drug.
Off-Label Uses
Beyond its official pain indication, hydromorphone is used in palliative and end-of-life care for symptoms beyond pain alone. In inpatient palliative care settings, one of the most common off-label uses is managing dyspnea, the distressing sensation of not being able to breathe that often accompanies advanced lung disease, heart failure, or late-stage cancer. Opioids like hydromorphone reduce the brain’s sensitivity to rising carbon dioxide levels, which eases that feeling of air hunger without necessarily changing oxygen levels.
How It Compares to Morphine
Hydromorphone works the same way morphine does, binding to opioid receptors in the brain and spinal cord to block pain signals. The key difference is potency. Research in cancer patients found that 1 mg of intravenous hydromorphone provides roughly the same pain relief as about 11.5 mg of oral morphine equivalent. When converting between intravenous and oral hydromorphone, the ratio is approximately 1 to 2.5, meaning 1 mg given by IV equals about 2.5 mg taken by mouth.
This higher potency doesn’t mean hydromorphone is “better” than morphine. It simply means smaller doses are needed to achieve the same effect, which can be useful when a patient needs to take less fluid volume (common with injections) or when morphine’s side effects, particularly itching or nausea, are problematic. Some patients tolerate one opioid better than another due to individual differences in how their bodies process these drugs.
Available Forms
Hydromorphone comes in several formulations designed for different pain situations:
- Immediate-release tablets in 2 mg, 4 mg, and 8 mg strengths, used for pain that needs to be addressed within the hour
- Extended-release tablets in 8 mg, 12 mg, 16 mg, and 32 mg strengths, designed to release the medication slowly over a full day
- Oral liquid at 1 mg per mL, which allows for precise dose adjustments, especially useful for people who have difficulty swallowing tablets
- Injectable solutions in concentrations from 1 mg/mL to 10 mg/mL, used in hospitals and clinical settings
The extended-release form is taken once daily. Immediate-release tablets and liquid are typically taken every 4 to 6 hours as needed. These are not interchangeable: accidentally substituting an extended-release dose as if it were immediate-release (or vice versa) can be dangerous.
Common Side Effects
Hydromorphone causes the same general side effects as other opioids. The most frequent are constipation, nausea, drowsiness, dizziness, and vomiting. Constipation is nearly universal with ongoing use and, unlike most other side effects, doesn’t improve as your body adjusts to the medication. Most people on regular hydromorphone need a bowel regimen from day one.
Respiratory depression, where breathing slows to a dangerous degree, is the most serious risk. This is more likely at higher doses, in people who are not opioid-tolerant, and when hydromorphone is combined with other sedating substances like benzodiazepines, alcohol, or sleep medications. Itching, sweating, and dry mouth are also reported, though generally less common than with morphine.
Who Needs Extra Caution
Your body processes hydromorphone through the liver and clears it through the kidneys, so impairment in either organ significantly changes how the drug behaves. People with moderate liver problems absorb about four times more hydromorphone into their bloodstream from the same dose compared to someone with normal liver function. In severe kidney impairment, the drug takes roughly 40 hours to clear the body instead of the usual 15 hours, and overall exposure triples.
Older adults, people with low thyroid function, adrenal insufficiency, or lung disease also process hydromorphone differently and typically start at lower doses. Anyone with a history of substance use disorder faces a higher risk of dependence, which is true of all opioids in this class.
Regulatory Classification
Hydromorphone is classified as a Schedule II controlled substance by the DEA, the same category as morphine, oxycodone, and fentanyl. This classification reflects both its accepted medical use and its high potential for abuse and physical dependence. In practical terms, this means prescriptions cannot include refills. Each new supply requires a new prescription, and many states impose additional monitoring through prescription drug monitoring programs.
Physical dependence develops with regular use over days to weeks, meaning sudden discontinuation causes withdrawal symptoms like muscle aches, anxiety, sweating, and insomnia. Dependence is a predictable physiological response and is distinct from addiction, which involves compulsive use despite harm. Both, however, are real concerns with any Schedule II opioid, and tapering off gradually under medical guidance is standard practice when the medication is no longer needed.